• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: Experience with fixed-dose formulation

    Thumbnail
    View/Open
    Article (303.9Kb)
    Date
    2006
    Author
    Obua, C.
    Gustafsson, L.L.
    Aguttu, C.
    Anokbonggoa, W.W.
    Ogwal-Okeng, J.W.
    Chiria, J.
    Hellgren, U.
    Metadata
    Show full item record
    Abstract
    Amodiaquine (AQ) is an affordable compound, chemically related to chloroquine (CQ) but often effective against CQ resistant Plasmodium falciparum. In Uganda, a pre-packed fixed-dose combination of CQ plus sulfadoxine/pyrimethamine (CQ + SP) called Homapak is used in the home based management of fever program (HBM).We performed a single blind randomized trial to determine the efficacy ofAQ+ SP in comparison with the fixed-dose CQ+ SP (Homapak) in the treatment of uncomplicated falciparum malaria in Ugandan children aged 6 months to 5 years. The study was done in 2004 at Walkuba Health Center, a sub-urban area in Jinja district, Uganda. Primary outcome was the day 14 per protocol clinical and parasitological response according to the WHO. A total of 183 children were included (mean age 28 months) and 90% completed 28 days of follow up. The day 14 adequate clinical and parasitological response was 70.9% for CQ+ SP and 97.4% for AQ+ SP (p < 0.001). In those given CQ+ SP, treatment failure rates for the 6 months to 2 years age group were much higher (48.2%) than in the older children (18.2%, p = 0.004). The day 28 PCR adjusted parasitological failure rates were also higher in the CQ+ SP (31.3%) than in the AQ+ SP group (13.1%) (p = 0.003), with a higher gametocyte carriage among the CQ+ SP group. We conclude that the efficacy of AQ+ SP was significantly superior to the fixed-dose CQ+ SP (Homapak), particularly among the youngest children. Thus, AQ could be used instead of CQ in combination with SP to improve the effectiveness against falciparum malaria in Uganda.
    URI
    http://hdl.handle.net/10570/2916
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV